Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma
Author:
Affiliation:
1. Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
2. Department of Radiology, Hyogo College of Medicine, Nishinomiya, Japan
Publisher
Informa UK Limited
Subject
Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/17476348.2019.1679119
Reference35 articles.
1. National survey of malignant mesothelioma and asbestos exposure in Japan
2. Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994-2013)
3. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
4. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
5. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anaesthetic and perioperative considerations for extrapleural pneumonectomy and extended pleurectomy/decortication: a scoping review protocol;BMJ Open;2024-05
2. Sarcomatoid malignant pleural mesothelioma associated with anti-Ma2-related paraneoplastic neurological syndrome: A case report;Current Problems in Cancer: Case Reports;2023-09
3. Do we still need to debate the merits of pleurectomy/decortication vs. extrapleural pneumonectomy for malignant pleural mesothelioma?;Translational Lung Cancer Research;2023-02
4. Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach;Translational Lung Cancer Research;2022-11
5. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma;Frontiers in Public Health;2022-07-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3